Trial Profile
A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary) ; Oseltamivir
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 17 Aug 2020 Results (n=160) of PK population analysis from two clinical studies: NV20234 and NV25118 assessing pharmacologic effects of oseltamivir in immunocompromised adult patients published in the British Journal of Clinical Pharmacology
- 10 Oct 2012 Planned End Date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 23 Jun 2010 New source identified and integrated (Memorial Sloan-Kettering Cancer Center, 10-004)